The Medicines Manufacturing Industry Partnership (MMIP) represents the voice of medicines manufacturers in the UK. It was established jointly by the Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class advanced centre for medicines manufacturing.
The UK's medicines industry is one of the country's leading manufacturing sectors, with exports worth over £20bn. The Partnership wants to ensure that the UK continues to be an attractive place for this high-value industry to secure exports, provide high skilled job opportunities and contribute to solving the country's productivity puzzle.
Find out more about MMIP in this KTN video
Working closely with key government organisations including the Medicines and Healthcare products Regulatory Authority (MHRA), UK Trade and Investment (UKTI), Innovate UK and the Office for Life Sciences (OLS), MMIP is examining the UK's position in medicines manufacturing and identifying opportunities for improvement.
MMIP is divided into five workstreams. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice.
These workstreams are:
- the technology and innovation landscape
- the fiscal environment
- the regulatory environment
- the skills environment
- Advanced Therapies manufacturing
MMIP also works to build the medicines manufacturing community.
MMIP Conference 2020
The 2020 MMIP conference was moved online due to the COVID-19 pandemic. Participants reviewed the overall impact of the pandemic on supply and manufacture of medicines for the UK, provided updates from several of the UK centres of manufacturing innovation, reviewed progress through the MMIP workstreams and looked to the future strategy for supporting medicines manufacturing in the UK. The slides are available here
MMIP is supported by the ABPI, the BioIndustry Association (BIA) and the Knowledge Transfer Network, and includes leadership from AstraZeneca, Cell and Gene Therapy Catapult, Centre for Process Innovation, Cobra Biologics, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Oxford Biomedica and Pfizer. It has a senior project director and additional dedicated resources provided by partners.
“The manufacture of modern medicines is one of our leading manufacturing sectors with exports worth over £20bn. MMIP is helping ensure we remain at the forefront of this highly competitive sector, building on the impressive work they have already led in areas like detailed innovation mapping and modern skills investment.” George Freeman MP, Chair of Prime Minister’s Policy Board
For the latest update:
For more information please email email@example.com